Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Seagen Inc. SGEN NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
47/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$171.82
-24.9%

Seagen Inc. (SGEN) is a Biotechnology company in the Healthcare sector, currently trading at $228.74. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is SGEN = $172 (-24.9% upside).

Financials: revenue is $2.0B, +44.8%/yr average growth. Net income is $610M (loss), growing at +290%/yr. Net profit margin is -31.1% (negative). Gross margin is 79.1% (-16.1 pp trend).

Balance sheet: total debt is $43M against $2.8B equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 2.12 (strong liquidity). Debt-to-assets is 1.2%. Total assets: $3.7B.

Analyst outlook: 14 / 37 analysts rate SGEN as buy (38%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 100/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 65/100 (Partial), Future 16/100 (Fail), Income 10/100 (Fail).

$171.82
▼ 24.88% Downside
Average Price Target
Based on 37 Wall Street analysts offering 12-month price targets for Seagen Inc., the average price target is $171.82, with a high forecast of $222.00, and a low forecast of $120.00.
Highest Price Target
$222.00
Average Price Target
$171.82
Lowest Price Target
$120.00

SGEN SharesGrow Score Overview

47/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 10/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 65/100
Gross margin is + market cap
FUTURE 16/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SGEN

✗
VALUE Fail
10/100
SGEN trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $172, implying -24.8% from the current price $229. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
SGEN: +44.8%/yr revenue is, +290%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
SGEN: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet SGEN: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 2.12 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
65/100
SGEN: Gross margin is 79.1% (-16.1 pp trend), $43B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 65/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
16/100
Analyst outlook: 14 / 37 analysts rate SGEN as buy (38%). Analyst consensus target is $172 (-24.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
SGEN: Net profit margin is -31.1%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range126.47-228.96
Volume19.39M
Avg Volume (30D)1.63M
Market Cap$43.15B
Beta (1Y)0.32
Share Statistics
EPS (TTM)-3.30
Shares Outstanding$184.68M
IPO Date2001-03-09
Employees3,256
CEODavid R. Epstein
Financial Highlights & Ratios
Revenue (TTM)$1.96B
Gross Profit$1.55B
EBITDA$-623.63M
Net Income$-610.31M
Operating Income$-612.97M
Total Cash$1.74B
Total Debt$43.47M
Net Debt$-276.47M
Total Assets$3.67B
Price / Earnings (P/E)-69.3
Price / Sales (P/S)21.99
Analyst Forecast
1Y Price Target$170.00
Target High$222.00
Target Low$120.00
Upside-25.7%
Rating ConsensusHold
Analysts Covering37
Buy 38% Hold 59% Sell 3%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS81181C1045

Price Chart

Track all markets on TradingView
SGEN
Seagen Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
126.47 52WK RANGE 228.96

People Also View

ALNY
ALNY
Alnylam Pharmaceuticals, Inc.
$339.41
+1.92%
 UTHR
UTHR
United Therapeutics Corporation
$578.54
+0.16%
 INCY
INCY
Incyte Corporation
$97.69
+2.24%
 ASND
ASND
Ascendis Pharma A/S
$249.84
+0.52%
 EXEL
EXEL
Exelixis, Inc.
$45.86
+2.00%
 MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 BMRN
BMRN
BioMarin Pharmaceutical Inc.
$55.47
+1.08%
 HALO
HALO
Halozyme Therapeutics, Inc.
$67.31
+0.49%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message